SEC Form 4 · accession 0001209191-19-000586
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence James Neil Cooper
Officer — Chief Executive Officer · Director
Period of report
Dec 29, 2018
Accepted (ET)
Jan 2, 2019 · 9:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 29, 2018 | F | 42,920 | $1.66 | D | 1,223,143 | D | |
| Common StockF1 | Dec 30, 2018 | F | 26,178 | $1.66 | D | 1,196,965 | D | |
| Common StockF1 | Dec 31, 2018 | F | 16,156 | $1.87 | D | 1,180,809 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.